Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- Brukinsa (zanubrutinib)
- lomitapide
Interactions between your drugs
lomitapide zanubrutinib
Applies to: lomitapide, Brukinsa (zanubrutinib)
Lomitapide may increase the blood levels of zanubrutinib in some patients. This may increase side effects such as rash, diarrhea, constipation, cough, hemorrhage, abnormal heart rhythm, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. You may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
lomitapide food
Applies to: lomitapide
Taking lomitapide with food may increase gastrointestinal side effects such as diarrhea, nausea, vomiting, stomach pain or discomfort, constipation, indigestion, and gas. The absorption of any other oral medication you may take can be affected if you develop diarrhea or vomiting. To reduce the risk of gastrointestinal intolerance, lomitapide should be taken once daily with a glass of water, without food, at least 2 hours after the evening meal. You should also follow a low-fat diet (<20% of total calories from fat) during treatment with lomitapide, and avoid the consumption of grapefruit or grapefruit juice. Since lomitapide may cause injury to the liver, you should have no more than one alcoholic drink per day. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
zanubrutinib food
Applies to: Brukinsa (zanubrutinib)
Grapefruit juice and Seville orange juice can increase the blood levels of zanubrutinib. This may increase side effects such as rash, diarrhea, constipation, cough, hemorrhage, development of other cancers, abnormal heart rhythm, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should avoid the consumption of Seville oranges, Seville orange juice, grapefruit and grapefruit juice during treatment with zanubrutinib. Be sure to take the medication at approximately the same time(s) everyday to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Epkinly
Epkinly is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.